GlassScriptPhysician profile
Michele Halby Mcmillan
NPI 1265479869
$2,043.02
in general payments reported to CMS, 2019-2025
25 companies · $327 in 2025
The $327 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $142 · 2021: $5.37 · 2022: $174 · 2023: $429 · 2024: $582 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $482.85 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $197.96 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $149.53 | 2024-2025 | |
| Corium, LLC | $123.48 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $119.03 | 2023-2024 | |
| Tris Pharma INC | $118.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $118.04 | 2020-2025 | Bexsero, Pediarix, Boostrix |
| Cranial Technologies, INC | $103.88 | 2022-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $94.54 | 2022-2025 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $89.31 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $76.28 | 2019-2025 | |
| Adlon Therapeutics L.P. | $73.72 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $44.54 | 2024 | Ycanth |
| Phadia US INC. | $27.02 | 2020-2024 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $24.28 | 2025 | Neffy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $23.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.64 | 2019 | |
| Photonicare INC | $22.90 | 2025 | Otosight Middle Ear Scope |
| Kyowa Kirin, INC. | $22.06 | 2024 | Crysvita |
| Genzyme Corporation | $19.60 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.92 | 2025 | Jornay Pm |
| Medtronic USA, INC. | $18.02 | 2019 | |
| Smith+Nephew, INC. | $17.49 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.21 | 2019 | |
| Medline Industries LP | $16.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Mcmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.